Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Olema Pharmaceuticals ( (OLMA) ) has provided an update.
Olema Pharmaceuticals has announced FDA clearance for its Investigational New Drug application for OP-3136, a promising small molecule targeting KAT6, implicated in breast cancer. The company is set to start Phase 1 clinical trials in early 2025. Additionally, Olema shared positive interim results from a Phase 1b/2 study combining palazestrant with ribociclib, showing encouraging tumor response and safety in treating advanced breast cancer, positioning palazestrant for further development.
For an in-depth examination of OLMA stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- HRIF, HUV: 2 Canadian ETFs to Boost Your Portfolio Returns
- Alphabet’s Google Asks FTC to Break Microsoft-OpenAI Exclusive Deal
- Amazon Autos Starts Offering Hyundai Cars for Sale to Customers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
